Skip to content
value.today

Resonate Blends, Inc.

KOAN
$12 Mlast known market cap, Jan 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
$2 M
For year ending December-2024
Net income
$-2 M
-112.1% margin
SEC filing
Employees
—

Resonate Blends, Inc. in brief

Resonate Blends, Inc. is a listed company in the Pharmaceutical industry, based in Calabasas, California, USA. Its last known market value was $12 M (January 2022); there is no current figure. In the year to December 2024 it had sales of $2 M and a net loss of $2 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Resonate Blends, Inc.

Effective as of March 5, 2025, the following has resigned as President /CEO of the Registrant, but shall remain as a member of the Board of Directors. Name Position James Morrison Director The Officer resigning has stated in his resignation letter that his resignation as President/CEO does not in any way imply or infer that there is any dispute or disagreement relating to the Company’s operations, policies or practices. Mr. Morrison will remain as member of the Board of Directors.

Our company engages in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine defined by the National Institute of Health using nutritionally designed products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual’s ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets. Research and development activities center on exploring other areas, such as Secretogues that can naturally enhance a person’s own growth hormone production and similar all natural bioactive formulations to enhance human performance safely, ethically, legally and utilizing known body mechanisms without the use of drugs.

From the company's annual report filed with the US SEC: read the report

Resonate Blends, Inc. timeline

6 events, 1994–2024
  1. 1994
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 1996
  4. ✎
    Renamed Brock International Inc
    Formerly Brock Control Systems Inc.
  5. 1998
  6. ✎
    Renamed Firstwave Technologies Inc
    Formerly Brock International Inc.
  7. 2007
  8. ✎
    Renamed Textmunication Holdings, Inc.
    Formerly Firstwave Technologies Inc.
  9. 2019
  10. ✎
    Renamed Resonate Blends, Inc.
    Formerly Textmunication Holdings, Inc..
  11. 2024
  12. 💰
    Record revenue of $2 million
    FY2024, the highest of the 6 years on record.

Events of Resonate Blends, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
—
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
51.6%
Operating margin
-89.5%
Return on equity
—
Liabilities / assets
273.0%
Revenue growth
+9400.0%
R&D / revenue
3.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $1M, net income $-8M$1MFY17Fiscal year ending Dec 2018: revenue $1M, net income $-0M$1MFY18Fiscal year ending Dec 2019: revenue $1M, net income $-4M$1MFY19Fiscal year ending Dec 2020: revenue —, net income $-2M—FY20Fiscal year ending Dec 2021: revenue $0M, net income $-5M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $1M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-1M$0MFY23Fiscal year ending Dec 2024: revenue $2M, net income $-2M$2MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$2M+9400.0%$-2M$-2M-112.1%
Dec 2023$0M-60.0%$-0M$-1M-7100.0%
Dec 2022$0M+66.7%$-1M$1M1300.0%
Dec 2021$0M—$-3M$-5M-16233.3%
Dec 2020——$-2M$-2M—
Dec 2019$1M-1.9%$-3M$-4M-349.5%
Dec 2018$1M+13.8%$-0M$-0M-31.8%
Dec 2017$1M—$-7M$-8M-813.8%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$-1M$0M$-1M$-0.02—
Dec 2023$0M$0M$0M$-0.02—
Dec 2022$-1M$0M$-1M$0.01—
Dec 2021$-3M$0M$-3M$-0.19—
Dec 2020$-1M$0M$-1M$-0.08—
Dec 2019$-1M$0M$-1M$-0.31—
Dec 2018$-0M$0M$-0M$-0.08—
Dec 2017$-0M$0M$-0M$-4.26—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$2M
Net income, trailing 12 months
$1M
RevenueNet income
Three months to Jun 2023: revenue $0M, net income $-0M$0MJun ’23Three months to Sep 2023: revenue —, net income $-0M—Sep ’23Three months to Dec 2023 (from the annual report): revenue —, net income $-0M—Dec ’23Three months to Mar 2024: revenue $0M, net income $-4M$0MMar ’24Three months to Jun 2024: revenue $1M, net income $-1M$1MJun ’24Three months to Sep 2024: revenue $1M, net income $-0M$1MSep ’24Three months to Dec 2024 (from the annual report): revenue $1M, net income $3M$1MDec ’24Three months to Mar 2025: revenue $0M, net income $-0M$0MMar ’25

Latest quarter to Mar 2025: revenue $0M (+330.0% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2025.

SEC filings

Official filings of Resonate Blends, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-2 M
Net income
$-2 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$2 M
Total liabilities
$5 M
Total equity
$-3 M

As of December-2024

Insider trading at Resonate Blends, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
1
since
Resonate Blends, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Wais AsefiChief Executive Officer, Director, 10% ownerGrant or award+2.50 M——2.76 MForm 4
filed Wais AsefiChief Executive Officer, Director, 10% ownerOther-1,212——255,029Form 4
filed Wais AsefiChief Executive Officer, Director, 10% ownerSell-1.21 M——3.82 MForm 4
filed Wais AsefiChief Executive Officer, Director, 10% ownerConversion-1.75 M——256,241Form 4
filed Wais AsefiChief Executive Officer, Director, 10% ownerConversion+2.00 M——2.00 MForm 4
filed Wais AsefiCEO, Director, 10% ownerGrant or award+2.00 B——2.01 BForm 5
filed Wais AsefiCEO, Director, 10% ownerOther-59.40 M——6.24 MForm 5
filed Wais AsefiCEO, Director, 10% ownerOther+4.00 M——4.00 MForm 5

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Resonate Blends, Inc. scorecard#

Passes 2 of the 8 checks that could be worked out. Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.02 vs -0.02Diluted EPS -0.02 in fiscal 2024 against -0.02 the year before (report's currency).
    • ✓Net income higher than five years earlier-$2 M-$2 M in fiscal 2024 against -$4 M in 2019.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2024.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2024.
    • ✗Operating margin above its peers' median-89.5%-89.5% against Pharmaceutical's median of 1.8% (74 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-89.5%-89.5% in fiscal 2024 against -8433.3% in 2021.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.2×Current ratio 0.20 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from Resonate Blends, Inc.'s statements, beside the median of Pharmaceutical.

Resonate Blends, Inc.: main financial ratios in 2024
Ratio2024Median of peers
Operating margin-89.5%1.8%
Net margin-112.1%-1.5%
Free cash flow margin-54.2%6.0%

4of 8on the Piotroski tests of financial strength

  • Net loss of $2 million.
  • Free cash flow was negative: -$1 million.
  • Shareholders' equity is negative: -$3 million.
  • Liabilities due within a year exceed current assets (current ratio 0.20).

Resonate Blends, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Resonate Blends, Inc.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Revenue1,896165027—1,0501,066944458r317
Cost of revenue6601143319—393315317103116
Gross profit1,236−98167.9—657752626355201
Research and development62—————————
Selling, general and administrative—————182133115r1,184r3,209
General and administrative1,201188r210r15967970————
Operating expenses2,9343021,4062,539r1,8143,178r1,0587,1751,266r3,209
Operating income−1,698−399−1,389−2,531r−1,814−3,178r−307−6,549−911r−3,007
Interest expense and finance costs————5578————
Provision for credit losses117161————————
Share of profit of associates—————−11−1.7−1.718—
Other non-operating income (expense)−436−1,0172,043−2,342r−143−321r−31r−1,099−2,432r−547
Income from continuing operations——654−4,873r−1,957r−3,510————
Income from discontinued operations————16−141————
Net income including minority interests———−5,763——————
Net income attributable to shareholders−2,133−1,416654−4,873r−1,941−3,670−340r−7,649−3,324r−3,555
Earnings per share, basic-0.02-0.020.01-0.16r-0.08r-0.31r-0.08r-4.26-25.18r-0.04
Earnings per share, diluted-0.02-0.020.01-0.19-0.08r-0.31r-0.08r-4.26-25.18r-0.04
Shares, weighted average (basic)9880753125114.22.013282
Shares, weighted average (diluted)—8075————1.80.1—
Balance sheet
Cash and cash equivalents8.06.964131143.1r6910—61
Receivables50————53152.83.83.1
Inventory——160246——————
Other current assets———1155—————
Current assets1,03497737527016910683133.864
Property, plant and equipment15152431————0.31.0
Investments in associates8050.10.10.10.125r451452454—
Total assets1,854992399301r169131r53451145865
Accounts payable1,197445320207r19964r225481292r181
Current liabilities5,054r3,1281,5464,403r1,165718r618r9841,700r1,166
Total liabilities—3,1281,5464,403r1,165718r618r9841,700r1,166
Retained earnings−28,870r−26,736−25,320−25,974r−21,101−19,160−15,490r−15,150−7,501r−4,177
Shareholders' equity−3,200r−2,136−1,147−4,102−996−587r−84r−473−1,242r−1,101
Total liabilities and equity1,854992399301r169131r53451145865
Shares outstanding11087754530r17r2.4r2.4r0.2r199r
Cash-flow statement
Depreciation and amortization178.87.74.7——————
Share-based compensation—392211400r3432,651—6,1154792,748
Cash from operating activities−1,02911−1,428−2,782r−1,381−791r−54r−146−433r−381
Capital expenditure−1.0−1.0−1.0−36r−1.0−1.0−1.0−45−24—
Cash from investing activities−358−805—−36r—−25—−4524—
Shares issued—10————————
Cash from financing activities1,3887361,4802,717r1,492819113r201348438
Change in cash1.1−5752−1011113.1r58r10−6156
Report10-K/A10-K/A10-K10-K10-K/A10-K10-K10-K/A10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Resonate Blends, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Auditor changed 1 · Change in control 2 · Acquisition or sale completed 2 · Directors and officers 4 · Material agreement 13 · Agreement ended 1 · New debt 7 · Unregistered share sale 3 · Shareholder vote 1

Resonate Blends, Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officersMaterial agreementShareholder vote8-K
Change in controlAcquisition or sale completedDirectors and officersMaterial agreement8-K/A
Change in controlAcquisition or sale completedDirectors and officersMaterial agreement8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Material agreementNew debt8-K
Material agreementNew debt8-K
Auditor changed8-K
Material agreementNew debt8-K
Unregistered share sale8-K
Material agreementNew debt8-K
Material agreementNew debt8-K
Material agreementNew debt8-K
Material agreementNew debt8-K
Agreement ended8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Mar 14, 2025

Acquisitions and funding#

Private share sales · funding history

Private share sales of Resonate Blends, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$1 MPrivate placement after listingUnder $2 million18equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Resonate Blends, Inc. compares in Pharmaceutical

  • Revenue$2 M · higher than 2% of 324
  • Net margin51.6% · higher than 99% of 313

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Resonate Blends, Inc.🇺🇸$12 M—51.6%—
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 7, 2022 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Resonate Blends, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Resonate Blends, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Resonate Blends, Inc.? Suggest a correction